Steroid Treatment for Hypereosinophilic Syndrome - Full Text View

Purpose

Background:

- Hypereosinophilic syndrome (HES) is a disorder in which the body has too many eosinophils (a type of white blood cell). Too many eosinophils in HES can cause damage to the heart, nerves, or skin. Certain drugs can help lower eosinophil counts to prevent tissue damage. Corticosteroids, such as prednisone, are used for initial therapy in this disorder. Although most people respond to prednisone, some people develop side effects from it, or do not respond very well to treatment. Better ways of determining the dose to give could help to decide on the best therapy for HES.

Objectives:

To determine whether a single-dose of prednisone can be used to predict which people with hypereosinophilia respond to treatment.
To study lack of response to steroid treatment in people with HES.

Eligibility:

Inclusion criteria:

Individuals with hypereosinophilic syndrome with high eosinophil counts.
Individuals who are willing to have blood drawn before and after getting steroids.

Exclusion criteria:

Individuals who are on more than 10mg of prednisone (or similar drug)
Individuals with hypereosinophilic syndrome who are on other medications that could interfere with the study
Women who are pregnant or breast-feeding
Individuals who have a known gene mutation associated with chronic eosinophilic leukemia
Children less than 18 years old who weigh less than 48kg or 106lb

Design:

Participants will have a screening visit with a physical exam and medical history. Blood and urine samples will be collected.
Participants will have a single dose of the steroid prednisone by mouth in the morning. Blood samples will be collected 4 hours after this dose.
On the day after the steroid dose, participants will provide another blood sample in the morning.
Participants will start to take prednisone daily when they return home. Blood samples will be collected weekly at the participant s doctor s office. The dose of prednisone will be lowered depending on the weekly eosinophil count. We will try to get each person on the lowest dose of prednisone possible that will control the disorder. Participants who do not respond or have severe side effects will be taken off prednisone. Other treatments will be considered for people who do not respond to steroids. The goal is to evaluate the response to prednisone. Our research will try to figure out why some people do not respond to steroids. Most people will complete the study within 6 to 16 weeks, depending on their response to prednisone.

Condition	Intervention	Phase
Hypereosinophilia	Drug: Corticosteroids	Phase 4


Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Assessment of Glucocorticoid Responsiveness and Mechanisms of Resistance in Hypereosinophilic Syndromes

Resource links provided by NLM:

Genetics Home Reference related topics: PDGFRA-associated chronic eosinophilic leukemia PDGFRB-associated chronic eosinophilic leukemia

MedlinePlus related topics: Steroids

Genetic and Rare Diseases Information Center resources: Hypereosinophilic Syndrome

U.S. FDA Resources

Further study details as provided by National Institutes of Health Clinical Center (CC):

Primary Outcome Measures:

To develop a model to determine whether a single dose steroid challenge can be used to predict GC responsiveness in subjects with HES [ Time Frame: completion of Study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

To define a group of GC non-responders and/or suboptimal responders for further study of the mechanisms and biologic correlates of GC resistance in HES [ Time Frame: 7-24 weeks post challenge. ] [ Designated as safety issue: No ]
To delineate some of the mechanisms of decreased GC responsiveness in GC-resistant subjects and to assess in-vitro correlates of therapeutic responsiveness in HES [ Time Frame: After a sufficient amount of patients from each patient typed has been enrolled and completed steroid taper ] [ Designated as safety issue: No ]


Estimated Enrollment:	100
Study Start Date:	November 2011
Estimated Study Completion Date:	December 2019
Estimated Primary Completion Date:	December 2018 (Final data collection date for primary outcome measure)

Detailed Description:

This study aims to develop a model to determine whether a single, oral, weight-based dose of glucocorticoid (GC) can predict clinical and biologic response to GC s over the long term in subjects with hypereosinophilic syndrome (HES). Subjects with FIP1L1/PDGFRA-negative HES, who are symptomatic with eosinophil count >1500/microL and receiving less than or equal to10 mg prednisone daily, will be enrolled. A single oral dose of prednisone (1 mg/kg rounded to the nearest 5mg) will be administered. Eosinophil count and various laboratory parameters will be assessed at 4 hours and 24 hours following prednisone administration (investigators will be blinded to the results of the eosinophil counts). The subjects will then begin GC therapy at 30 mg prednisone daily followed by a standardized taper. The lowest dose of GC at which symptoms and eosinophilia are controlled will be compared to the change in eosinophil count at 4 and 24 hours post-challenge. Mechanisms and in vitro correlates of GC resistance will also be explored.

Eligibility


Ages Eligible for Study:	7 Years to 100 Years (Child, Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

SUBJECT INCLUSION CRITERIA:

Subjects on Protocol #94-I-0079 will be eligible for participation in the study only if all of the following criteria apply:

Subject meets diagnostic criteria for HES (AEC >1500/microL, absence of a secondary cause and signs and/or symptoms attributable to the eosinophilia)
Willingness to perform the timed steroid challenge
Appropriate candidate for GC treatment after challenge
Willingness to have samples stored for future research

SUBJECT EXCLUSION CRITERIA:

A subject will not be eligible to participate in the study if any of the following apply:

Receiving >10 mg prednisone or equivalent at the time of enrollment.
Receiving less than or equal to 10 mg of prednisone or equivalent but have not been on a fixed dose for at least 3 weeks (subjects on a current corticosteroid taper will be excluded).
AEC less than or equal to 1500/microl at the time of enrollment.
Use of immunomodulatory medications, (other than less than or equal to 10 mg/day prednisone) including but not limited to biologics, within the past 6 months.
Pregnant at the time of evaluation.
Have a known mutation in the FIP1L1-PDGFR gene.
Any condition that, in the opinion of the investigator, places the subject at undue risk by participating in the protocol.
Weight less than 48 kg (106 lbs) in subjects less than 18 years of age.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01524536

Contacts


Contact: Nicole C Holland-Thomas, R.N.	(301) 402-5969	hollandnc@mail.nih.gov
Contact: Paneez Khoury, M.D.	(301) 402-3673	khouryp@niaid.nih.gov

Locations


United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike	Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL) 800-411-1222 ext TTY8664111010 prpl@mail.cc.nih.gov

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)

Investigators


Principal Investigator:	Paneez Khoury, M.D.	National Institute of Allergy and Infectious Diseases (NIAID)

More Information

Additional Information:

NIH Clinical Center Detailed Web Page This link exits the ClinicalTrials.gov site

Publications:

Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE, Leiferman KM, Nutman TB, Pfab F, Ring J, Rothenberg ME, Roufosse F, Sajous MH, Sheikh J, Simon D, Simon HU, Stein ML, Wardlaw A, Weller PF, Klion AD. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009 Dec;124(6):1319-25.e3. doi: 10.1016/j.jaci.2009.09.022. Epub .

Prin L, Lefebvre P, Gruart V, Capron M, Storme L, Formstecher P, Loiseau S, Capron A. Heterogeneity of human eosinophil glucocorticoid receptor expression in hypereosinophilic patients: absence of detectable receptor correlates with resistance to corticotherapy. Clin Exp Immunol. 1989 Dec;78(3):383-9.

Hamilos DL, Leung DY, Muro S, Kahn AM, Hamilos SS, Thawley SE, Hamid QA. GRbeta expression in nasal polyp inflammatory cells and its relationship to the anti-inflammatory effects of intranasal fluticasone. J Allergy Clin Immunol. 2001 Jul;108(1):59-68.


Responsible Party:	National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:	NCT01524536 History of Changes
Other Study ID Numbers:	120026 12-I-0026
Study First Received:	February 1, 2012
Last Updated:	August 31, 2016
Health Authority:	United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):


Hypereosinophilia Hypereosinophilic Syndrome Corticosteroids Therapy HES

Additional relevant MeSH terms:


Syndrome Hypereosinophilic Syndrome Eosinophilia Disease	Pathologic Processes Leukocyte Disorders Hematologic Diseases

ClinicalTrials.gov processed this record on September 27, 2016